Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Yvette J. Johnson x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To determine the baseline costs of bovine leukemia virus (BLV) infection, including costs of clinical disease and subclinical infection, in a dairy herd representative of the mid-Atlantic region and compare these costs with the cost of a test-and-manage BLV control program.

Design—Stochastic spreadsheet model.

Sample Population—A commercial Holstein dairy herd with 100 milking cows.

Procedures—A spreadsheet model was developed. The overall cost of infection included the cost of clinical disease (ie, lymphosarcoma [LS]) and the effects of subclinical infection on milk production and premature culling. Model input values and distributions were designed to reflect economic conditions in the mid-Atlantic region. Relative costs of infection and control were calculated for infection prevalences of 20, 50, and 80%.

Results—Estimated mean cost to the producer per case of LS was $412; for a herd with a 50% prevalence of BLV infection, annual incidence of LS was 0.66. Mean annual cost of subclinical infection at a 50% prevalence of infection was $6,406. Mean annual cost of a test-and-manage control program was $1,765. The cost of clinical disease and subclinical infection varied substantially with the prevalence of infection, whereas the cost of control varied with herd size.

Conclusions and Clinical Relevance—Results suggested that a basic BLV control program may be economically beneficial in herds in which the prevalence of BLV infection is ≥ 12.5%. Farm-specific considerations may factor prominently when weighing the costs and benefits of an individual BLV control program. (J Am Vet Med Assoc 2003;223:346–352)

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine the association between serologic status for bovine leukemia virus (BLV) and culling rates by use of survival times in a commercial Holstein dairy herd.

Design—Longitudinal study.

Animals—593 milking cows.

Procedure—Cattle were tested for antibodies against BLV by use of agar gel immunodiffusion or ELISA 4 times each year from 1989 to 1993 and then annually through 1999. Dates of birth, first calving, and culling or death were obtained from Dairy Herd Improvement Association records. Most cows were enrolled in the study on the date of first calving. Survival times were compared among seropositive, seronegative, and seroconverted cows with the Kaplan-Meier method and a Cox regression model stratified on the basis of year of birth.

Results—Complete records were available for 593 of 685 (87%) cattle in the dairy herd during the study period. Median survival time for all cows was 31.7 months. Survival times, which correspond to cull rates, did not differ significantly between seropositive and seronegative cattle, whereas cattle that seroconverted during the study had a significantly longer survival time. Year of birth was positively and significantly associated with survival time.

Conclusions and Clinical Relevance—BLV serologic status was not associated with cull rate as measured by survival time in this dairy herd. This finding is in contrast to results of studies that used survival analysis techniques; our results may influence management decisions concerning BLV. (J Am Vet Med Assoc 2003;223:229–231)

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To compare the temporal and spatial distribution of cases of blastomycosis among humans and dogs in Illinois.

Design—Retrospective cross-sectional survey.

Sample—Human and canine populations in Illinois from 2001 through 2007.

Procedures—For each year, human population data were obtained from the US Census Bureau, and the total number of dogs was estimated by use of a human population-based formula. Data regarding infections with Blastomyces dermatitidis in humans were accessed from the Illinois Department of Public Health. Data regarding B dermatitidis infections in dogs were acquired through a survey of a random sample of the 747 veterinary medical practices in Illinois. Statistical analyses of human and canine data were performed by use of t tests, ANOVA, odds ratio assessment, and regression modeling.

Results—Estimated annual incidence of human cases of blastomycosis in Illinois increased from 3.8 to 10.7 cases/1 million persons/y from 2001 through 2007. Analysis of data from 221 veterinary practices revealed that the mean estimated annual incidence of canine cases of blastomycosis was 8.3 times the mean estimated annual incidence of human cases, with a similar pattern of change and regional distributions. Thirty-eight counties reported either human or canine cases but not both.

Conclusions and Clinical Relevance—The estimated annual incidence of blastomycosis in humans and dogs in Illinois increased during the period of interest. Veterinarians, physicians, and public health agencies should be encouraged to communicate with each other regarding diagnoses of blastomycosis in either species to facilitate early diagnosis and treatment.

Restricted access
in Journal of the American Veterinary Medical Association